Financials Biocartis Group NV
Equities
BCART
BE0974281132
Medical Equipment, Supplies & Distribution
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.29 EUR | +1.05% | -.--% | -.--% |
Valuation
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Capitalization 1 | 610.2 | 510.5 | 322.5 | 267.6 | 208 | 48.52 |
Enterprise Value (EV) 1 | 532.8 | 482.3 | 310.4 | 294.5 | 308.7 | 144.8 |
P/E ratio | -12.8 x | -10.6 x | -5.01 x | -4.18 x | -2.91 x | -0.49 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 26.4 x | 17.8 x | 8.55 x | 4.82 x | 3.79 x | 0.84 x |
EV / Revenue | 23.1 x | 16.8 x | 8.23 x | 5.3 x | 5.62 x | 2.5 x |
EV / EBITDA | -13.8 x | -12.2 x | -6.09 x | -7.23 x | -5.78 x | -3.55 x |
EV / FCF | -18.1 x | -15 x | -8.21 x | -14.1 x | -7.44 x | -5.07 x |
FCF Yield | -5.53% | -6.66% | -12.2% | -7.07% | -13.4% | -19.7% |
Price to Book | 4.61 x | 5.84 x | 3.82 x | 7.27 x | -6.14 x | -1.62 x |
Nbr of stocks (in thousands) | 51,102 | 51,361 | 56,382 | 57,546 | 57,546 | 91,894 |
Reference price 2 | 11.94 | 9.940 | 5.720 | 4.650 | 3.615 | 0.5280 |
Announcement Date | 05/04/18 | 04/04/19 | 02/04/20 | 01/04/21 | 31/03/22 | 11/04/23 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net sales 1 | 23.11 | 28.65 | 37.73 | 55.56 | 54.9 | 57.98 |
EBITDA 1 | -38.61 | -39.49 | -50.98 | -40.74 | -53.38 | -40.78 |
EBIT 1 | -43.59 | -43.62 | -55.6 | -45.16 | -58.04 | -45.87 |
Operating Margin | -188.62% | -152.24% | -147.36% | -81.29% | -105.72% | -79.12% |
Earnings before Tax (EBT) 1 | -45.32 | -48.26 | -64.17 | -63.16 | -71.72 | -65.62 |
Net income 1 | -41.96 | -48.15 | -64.07 | -62.93 | -71.47 | -65.38 |
Net margin | -181.57% | -168.07% | -169.8% | -113.27% | -130.19% | -112.77% |
EPS 2 | -0.9294 | -0.9400 | -1.143 | -1.112 | -1.242 | -1.080 |
Free Cash Flow 1 | -29.45 | -32.13 | -37.82 | -20.83 | -41.48 | -28.54 |
FCF margin | -127.43% | -112.13% | -100.24% | -37.49% | -75.56% | -49.22% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 05/04/18 | 04/04/19 | 02/04/20 | 01/04/21 | 31/03/22 | 11/04/23 |
Balance Sheet Analysis
Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | 26.9 | 101 | 96.2 |
Net Cash position 1 | 77.4 | 28.2 | 12.1 | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | -0.66 x | -1.885 x | -2.36 x |
Free Cash Flow 1 | -29.4 | -32.1 | -37.8 | -20.8 | -41.5 | -28.5 |
ROE (net income / shareholders' equity) | -36.6% | -43.9% | -74.6% | -104% | -4,884% | 204% |
ROA (Net income/ Total Assets) | -16.9% | -17% | -17% | -11.8% | -20.6% | -22.3% |
Assets 1 | 248.4 | 283.1 | 375.8 | 533.8 | 347.8 | 292.8 |
Book Value Per Share 2 | 2.590 | 1.700 | 1.500 | 0.6400 | -0.5900 | -0.3300 |
Cash Flow per Share 2 | 2.210 | 1.240 | 3.170 | 2.150 | 0.9300 | 0.2800 |
Capex 1 | 3.16 | 5.57 | 2.12 | 3.01 | 3.69 | 1.57 |
Capex / Sales | 13.66% | 19.44% | 5.62% | 5.41% | 6.71% | 2.71% |
Announcement Date | 05/04/18 | 04/04/19 | 02/04/20 | 01/04/21 | 31/03/22 | 11/04/23 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-.--% | 29.08M | |
+72.92% | 12.38B | |
-19.68% | 7.92B | |
+16.20% | 7.2B | |
+6.78% | 5.84B | |
+7.49% | 5.07B | |
+23.97% | 4.53B | |
-20.08% | 3.88B | |
-41.54% | 2.23B | |
+1.24% | 2.02B |
- Stock Market
- Equities
- BCART Stock
- Financials Biocartis Group NV